Therapy Areas: Inflammatory Diseases
Celgene Shows Data from Ongoing Studies of Liso-Cel in Patients with Difficult-to-Treat Blood Cancers at ASCO 2019
6 June 2019 - - US-based biopharmaceutical company Celgene Corp. (NASDAQ: CELG) has presented data from the TRANSCEND CLL 004 and TRANSCEND NHL 001 trials studying the investigational anti-CD19 chimeric antigen receptor T-cell therapy lisocabtagene maraleucel (liso-cel; JCAR017) in patients with B-cell blood cancers at the American Society of Clinical Oncology annual meeting in Chicago, the company said.
Updated results from the ongoing, open-label multicenter phase 1/2 TRANSCEND CLL 004 study (Abstract #7501) of liso-cel in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) were presented in an oral presentation.
The data included safety and efficacy findings from 23 patients who received liso-cel infusion at one of two dose levels: 50 × 106 or 100 × 106total CAR-positive T cells following lymphodepleting chemotherapy.
All patients had been previously treated with ibrutinib, and more than half had received prior venetoclax. The median number of lines of prior therapy was five and 83% of patients had high-risk cytogenetic features.
In the study, 22 of 23 patients were evaluable for response. The best overall response rate was 82% (18/22), with 46% (10/22) of patients achieving complete remission with or without complete blood count recovery (CR/CRi). Of 20 patients evaluable for minimal residual disease, 75% (15/20) achieved undetectable MRD by blood measures (sensitivity, 10-4) and 65% (13/20) achieved uMRD by bone marrow measures (sensitivity, 10-4).
Responses have been durable, with 83% of patients who were in CR/CRi at six months post liso-cel infusion showing ongoing response.
The most common treatment-emergent adverse events (TEAEs) of any grade were anemia, cytokine release syndrome (CRS; 74%), thrombocytopenia, neutropenia, and leukopenia.
There were two patients with dose-limiting toxicities among the 14 patients treated at 100 × 106 total CAR-positive T cells: grade 4 hypertension in one patient; and grade 3 encephalopathy, grade 3 muscle weakness and grade 4 tumor lysis syndrome in the other patient.
Across 23 patients evaluable for safety, TEAEs of note included grade 3 CRS, grade ≥ 3 neurological events, and grade ≥ 3 tumor lysis syndrome. No grade 5 CRS or neurological events occurred.
In addition to these findings from TRANSCEND CLL 004, preliminary safety and efficacy data were presented from two subgroup analyses from the ongoing, open-label multicenter phase 1 TRANSCEND NHL 001 trial evaluating liso-cel in patients with R/R B-cell non-Hodgkin's lymphoma at one of two dose levels: 50 × 106 or 100 × 106 total CAR-positive T cells following lymphodepleting chemotherapy.
The data included results from a subgroup of patients with secondary central nervous system lymphoma (Abstract #7515) and from patients with R/R mantle cell lymphoma (MCL; n=17) (Abstract #7516). These were highlighted in a poster discussion session on Monday, June 3.
Patients had secondary CNS lymphoma at the time of first treatment (n=7; 6 DLBCL, 1 MCL) or retreatment with liso-cel (n=2 DLBCL), and neurological events and CRS were observed in only one patient.
Of the 6 DLBCL patients with CNS lymphoma at the time of first retreatment with liso-cel, 4 achieved complete responses, 2 of whom are in sustained remission at more than 8 and 17 months, respectively.
The data in patients with MCL included safety and preliminary efficacy findings for 17 treated patients. The most common grade ≥ 3 TEAEs were thrombocytopenia, anemia and neutropenia. Grade ≥ 3 CRS and neurological events occurred in 6% and 12% of patients, respectively. One fatal event of tumor lysis syndrome was observed.
The best overall response rate across dose levels was 71% (12/17); the best complete response rate was 53%. These results are consistent with those seen in all patients treated with liso-cel in the TRANSCEND NHL 001 study.
Liso-cel is not approved in any country.
Liso-cel is an investigational defined composition CD19-directed CAR T-cell product candidate using a 4-1BB costimulatory domain. Celgene's lead CAR T trial, TRANSCEND NHL-001, is studying liso-cel in adult patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, follicular lymphoma Grade 3B and mantle cell lymphoma.
Celgene is committed to advancing the field of immune cell therapy from pursuing scientific breakthroughs to enabling routine clinical use so that more patients may benefit from the research that may ultimately lead to these emerging treatments.
Celgene is building a portfolio of cell therapies supported by more than 15 years of development, including several chimeric antigen receptor T-cell agents in registrational trials across multiple disease states, and a growing early-stage pipeline that expands cell therapy targets and technologies.
The company is advancing cell therapies in diffuse large B-cell lymphoma, multiple myeloma and other B-cell malignancies. These efforts underscore a belief in the promise of cell therapy to redefine the way patients fight cancer and to potentially transform how these diseases are treated.
Celgene Corp., headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialisation of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Login
Username:

Password: